The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker Eli Lilly to become the largest pharmaceutical company in the world by market capitalization. Eli Lilly Chair and CEO Dave Ricks joined Goldman Sachs’ John Waldron for a Goldman Sachs Talks session to discuss Lilly’s journey with medicine for chronic weight management, his view on how medicine is changing and the new problems it’s attempting to solve, and how he leads an organization where innovation is a necessity.
This episode was recorded on March 12, 2024.
Our weekly newsletter with insights and intelligence from across the firm
By submitting this information, you agree to receive marketing emails from Goldman Sachs and accept our privacy policy. You can opt-out at any time.